You just read:

Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv™ (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis

News provided by

Amgen

10 Jan, 2017, 16:12 ET